Development of second generation EP2 antagonists with high selectivity
摘要:
EP2 receptor has emerged as an important biological target for therapeutic intervention. In particular, it has been shown to exacerbate disease progression of a variety of CNS and peripheral diseases. Deletion of the EP2 receptor in mouse models recapitulates several features of the COX-2 inhibition, thus presenting a new avenue for anti-inflammatory therapy which could bypass some of the adverse side effects observed by the COX-2 inhibition therapy. We have recently reported a cinnamic amide class of EP2 antagonists with high potency, but these compounds exhibited a moderate selectivity against prostanoid receptor DP1. Moreover they possess acrylamide moiety in the structure, which may result in liver toxicity over longer period of use in a chronic disease model. Thus, we now developed a second generation compounds that devoid of the acrylamide functionality and possess high potency and improved (>1000-fold) selectivity to EP2 over other prostanoid receptors. (C) 2014 Elsevier Masson SAS. All rights reserved.
Multifunctional polymers with interpenetrating structures: luminescence sensing, ECL behaviors, selective detection of Fe<sup>3+</sup> ion and rapid removal of anionic dyes
作者:Lingshu Meng、Lun Zhao、Guanlin Guo、Xin Liu
DOI:10.1039/d0nj01066a
日期:——
Three unprecedented metal–organic frameworks with interspersed structures have been synthesized and structurally characterized.
已合成并表征了三种具有间隔结构的前所未有的金属有机框架。
Development of second generation EP2 antagonists with high selectivity
作者:Thota Ganesh、Jianxiong Jiang、Ray Dingledine
DOI:10.1016/j.ejmech.2014.05.076
日期:2014.7
EP2 receptor has emerged as an important biological target for therapeutic intervention. In particular, it has been shown to exacerbate disease progression of a variety of CNS and peripheral diseases. Deletion of the EP2 receptor in mouse models recapitulates several features of the COX-2 inhibition, thus presenting a new avenue for anti-inflammatory therapy which could bypass some of the adverse side effects observed by the COX-2 inhibition therapy. We have recently reported a cinnamic amide class of EP2 antagonists with high potency, but these compounds exhibited a moderate selectivity against prostanoid receptor DP1. Moreover they possess acrylamide moiety in the structure, which may result in liver toxicity over longer period of use in a chronic disease model. Thus, we now developed a second generation compounds that devoid of the acrylamide functionality and possess high potency and improved (>1000-fold) selectivity to EP2 over other prostanoid receptors. (C) 2014 Elsevier Masson SAS. All rights reserved.